Intel (INTC) 10-Q 22 Oct 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page shares in Millions	9 Months Ended
	Sep. 25, 2021shares
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 25, 2021
Entity File Number	000-06217
Entity Registrant Name	INTEL CORPORATION
Entity Central Index Key	0000050863
Current Fiscal Year End Date	--12-25
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1672743
Entity Address, Address Line One	2200 Mission College Boulevard,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054-1549
City Area Code	(408)
Local Phone Number	765-8080
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	INTC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	4,067

Consolidated Condensed Statemen

Consolidated Condensed Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Income Statement [Abstract]
Net revenue	$ 19,192	$ 18,333	$ 58,496	$ 57,889
Cost of sales	8,446	8,592	25,690	25,625
Gross margin	10,746	9,741	32,806	32,264
Research and development	3,803	3,272	11,141	9,901
Marketing, general and administrative	1,674	1,435	4,601	4,423
Restructuring and other charges	42	(25)	2,597	146
Operating expenses	5,519	4,682	18,339	14,470
Operating income	5,227	5,059	14,467	17,794
Gains (losses) on equity investments, net	1,707	56	2,370	212
Interest and other, net	(76)	(74)	(328)	(416)
Income before taxes	6,858	5,041	16,509	17,590
Provision for taxes	35	765	1,264	2,548
Net income	$ 6,823	$ 4,276	$ 15,245	$ 15,042
Earnings per share - Basic (in dollars per share)	$ 1.68	$ 1.02	$ 3.76	$ 3.55
Earnings per share - Diluted (in dollars per share)	$ 1.67	$ 1.02	$ 3.73	$ 3.52
Weighted average shares of common stock outstanding:
Basic (shares)	4,061	4,188	4,055	4,233
Diluted (shares)	4,086	4,211	4,089	4,269

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 6,823	$ 4,276	$ 15,245	$ 15,042
Changes in other comprehensive income, net of tax:
Net unrealized holding gains (losses) on derivatives	(46)	206	(390)	257
Actuarial valuation and other pension benefits (expenses), net	13	11	38	34
Translation adjustments and other	(19)	(5)	(44)	49
Other comprehensive income (loss)	(52)	212	(396)	340
Total comprehensive income	$ 6,771	$ 4,488	$ 14,849	$ 15,382

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 25, 2021	Dec. 26, 2020
Current assets:
Cash and cash equivalents	$ 7,870	$ 5,865
Short-term investments	4,004	2,292
Trading assets	22,761	15,738
Accounts receivable	8,400	6,782
Inventories	9,798	8,427
Assets Held-for-sale	6,398	5,400
Other current assets	2,073	2,745
Total current assets	61,304	47,249
Property, plant and equipment, net of accumulated depreciation of $83,424 ($77,645 as of December 26, 2020)	59,733	56,584
Equity Investments	6,050	5,152
Other long-term investments	953	2,192
Goodwill	26,786	26,971
Identified intangible assets, net	7,684	9,026
Other long-term assets	5,452	5,917
Total assets	167,962	153,091
Current liabilities:
Short-term debt	4,694	2,504
Accounts payable	6,792	5,581
Accrued compensation and benefits	4,026	3,999
Other accrued liabilities	14,060	12,670
Total current liabilities	29,572	24,754
Debt	35,610	33,897
Contract Liabilities	62	1,367
Income taxes payable, non-current	4,223	4,578
Deferred income taxes	3,019	3,843
Other long-term liabilities	5,389	3,614
Contingencies (Note 13)
Stockholders’ equity:
Common stock and capital in excess of par value, 4,067 issued and outstanding (4,062 issued and outstanding as of December 26, 2020)	27,592	25,556
Accumulated other comprehensive income (loss)	(1,147)	(751)
Retained earnings	63,642	56,233
Total stockholders’ equity	90,087	81,038
Total liabilities and stockholders’ equity	$ 167,962	$ 153,091

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Sep. 25, 2021	Dec. 26, 2020
Assets
Accumulated depreciation	$ 83,424	$ 77,645
Stockholders’ equity:
Common stock, shares issued	4,067	4,062
Common stock, shares outstanding	4,067	4,062

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 5,865	$ 4,194
Cash flows provided by (used for) operating activities:
Net income	15,245	15,042
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	7,357	7,925
Share-based compensation	1,587	1,393
Restructuring and other charges	2,597	146
Amortization of intangibles	1,361	1,311
(Gains) losses on equity investments, net	(1,113)	(105)
Changes in assets and liabilities:
Accounts receivable	(1,618)	525
Inventories	(1,212)	(570)
Accounts payable	1,095	355
Accrued compensation and benefits	(16)	(569)
Prepaid supply agreements	(1,577)	(91)
Income taxes	(570)	493
Other assets and liabilities	1,058	(361)
Total adjustments	8,949	10,452
Net cash provided by operating activities	24,194	25,494
Cash flows provided by (used for) investing activities:
Additions to property, plant and equipment	(11,579)	(10,392)
Additions to held for sale NAND property, plant, and equipment	1,118	0
Purchases of available-for-sale debt investments	(3,983)	(6,323)
Maturities and sales of available-for-sale debt investments	3,457	5,037
Purchases of trading assets	(26,343)	(14,744)
Maturities and sales of trading assets	18,813	11,227
Other investing	620	83
Net cash used for investing activities	(20,133)	(15,112)
Cash flows provided by (used for) financing activities:
Issuance of long-term debt, net of issuance costs	4,974	10,247
Repayment of debt and debt conversion	(500)	(4,525)
Proceeds from sales of common stock through employee equity incentive plans	1,016	897
Repurchase of common stock	(2,415)	(12,229)
Accelerated share repurchase forward agreements	0	2,000
Payment of dividends to stockholders	(4,231)	(4,215)
Other financing	(900)	605
Net cash provided by (used for) financing activities	(2,056)	(11,220)
Net increase (decrease) in cash and cash equivalents	2,005	(838)
Cash and cash equivalents, end of period	7,870	3,356
Supplemental disclosures of noncash investing activities and cash flow information:
Acquisition of property, plant, and equipment included in accounts payable and accrued liabilities	(2,693)	(2,752)
Interest, net of capitalized interest	271	459
Income taxes, net of refunds	$ 1,831	$ 1,986

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Stockholders' Equity Statement - USD ($) shares in Millions, $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjusted Balance	Common Stock and Capital in Excess of Par Value	Common Stock and Capital in Excess of Par ValueCumulative Effect, Period of Adoption, Adjusted Balance	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss)Cumulative Effect, Period of Adoption, Adjusted Balance	Retained Earnings	Retained EarningsCumulative Effect, Period of Adoption, Adjusted Balance	[1]
Total stockholders' equity, beginning at Dec. 28, 2019	$ 77,504		$ 25,261		$ (1,280)		$ 53,523
Common stock, shares outstanding, beginning (in shares) at Dec. 28, 2019			4,290
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	15,042						15,042
Other comprehensive income (loss)	340				340
Employee equity incentive plans and other	1,014		$ 1,014
Employee equity incentive plans (in shares)			54
Share-based compensation	1,393		$ 1,393
Temporary equity reduction	155		155
Convertible debt	(750)		(750)
Repurchase of common stock	(12,109)		$ (1,413)				(10,696)
Repurchase of common stock (in shares)			(237)
Accelerated share repurchase forward agreements	(2,000)		$ (2,000)
Restricted stock unit withholdings	(460)		$ (325)				(135)
Restricted stock unit withholdings (in shares)			(9)
Cash dividends declared	(5,575)						(5,575)
Total stockholders' equity, ending at Sep. 26, 2020	74,554		$ 23,335		(940)		52,159
Common stock, shares outstanding, ending (in shares) at Sep. 26, 2020			4,098
Total stockholders' equity, beginning at Jun. 27, 2020	82,010		$ 25,516		(1,152)		57,646
Common stock, shares outstanding, beginning (in shares) at Jun. 27, 2020			4,253
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	4,276						4,276
Other comprehensive income (loss)	212				212
Employee equity incentive plans and other	385		$ 385
Employee equity incentive plans (in shares)			12
Share-based compensation	452		$ 452
Repurchase of common stock	(8,000)		$ (993)				(7,007)
Repurchase of common stock (in shares)			(166)
Accelerated share repurchase forward agreements	(2,000)		$ (2,000)
Restricted stock unit withholdings	(25)		$ (25)				0
Restricted stock unit withholdings (in shares)			(1)
Cash dividends declared	(2,756)						(2,756)
Total stockholders' equity, ending at Sep. 26, 2020	74,554		$ 23,335		(940)		52,159
Common stock, shares outstanding, ending (in shares) at Sep. 26, 2020			4,098
Total stockholders' equity, beginning at Dec. 26, 2020	$ 81,038	$ 81,073		$ 25,556		$ (751)		$ 56,268
Common stock, shares outstanding, beginning (in shares) at Dec. 26, 2020	4,062			4,062
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 15,245						15,245
Other comprehensive income (loss)	(396)				(396)
Employee equity incentive plans and other	1,015		$ 1,015
Employee equity incentive plans (in shares)			52
Share-based compensation	1,587		$ 1,587
Temporary equity reduction	0		0
Convertible debt	0		0
Repurchase of common stock	(2,415)		$ (249)				(2,166)
Repurchase of common stock (in shares)			(40)
Accelerated share repurchase forward agreements	0		$ 0
Restricted stock unit withholdings	(377)		$ (317)				(60)
Restricted stock unit withholdings (in shares)			(7)
Cash dividends declared	(5,645)						(5,645)
Total stockholders' equity, ending at Sep. 25, 2021	$ 90,087		$ 27,592		(1,147)		63,642
Common stock, shares outstanding, ending (in shares) at Sep. 25, 2021	4,067		4,067
Total stockholders' equity, beginning at Jun. 26, 2021	$ 85,207		$ 26,655		(1,095)		59,647
Common stock, shares outstanding, beginning (in shares) at Jun. 26, 2021			4,057
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	6,823						6,823
Other comprehensive income (loss)	(52)				(52)
Employee equity incentive plans and other	427		$ 427
Employee equity incentive plans (in shares)			11
Share-based compensation	543		$ 543
Repurchase of common stock	0		$ 0				0
Repurchase of common stock (in shares)			0
Accelerated share repurchase forward agreements	0		$ 0
Restricted stock unit withholdings	(37)		$ (33)				(4)
Restricted stock unit withholdings (in shares)			(1)
Cash dividends declared	(2,824)						(2,824)
Total stockholders' equity, ending at Sep. 25, 2021	$ 90,087		$ 27,592		$ (1,147)		$ 63,642
Common stock, shares outstanding, ending (in shares) at Sep. 25, 2021	4,067		4,067
[1]	The retained earnings balance as of December 26, 2020 includes an opening balance adjustment made as a result of the adoption of a new accounting standard in 2021.

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Stockholders' Equity Statements of Stockholders' Equity (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Retained Earnings
Common Stock, Dividends, Per Share, Declared	$ 0.70	$ 0.66	$ 1.39	$ 1.32

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 25, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1 : Basis of Presentation We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K. We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with the Consolidated Financial Statements in our 2020 Form 10-K where we include additional information about our policies and the methods and assumptions used in our estimates.

Operating Segments

Operating Segments	9 Months Ended
	Sep. 25, 2021
Segment Reporting [Abstract]
Operating Segments	Note 2 : Operating Segments We manage our business through the following operating segments: ▪ CCG ▪ DCG ▪ IOTG ▪ Mobileye ▪ NSG ▪ PSG We derive a substantial majority of our revenue from platform products, which are our principal products and considered as one product class. We offer platform products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package based on Intel architecture. Platform products are used in various form factors across our CCG, DCG, and IOTG operating segments. Our non-platform, or adjacent products, can be combined with platform products to form comprehensive platform solutions to meet customer needs. CCG and DCG are our reportable operating segments. IOTG, Mobileye, NSG, and PSG do not meet the quantitative thresholds to qualify as reportable operating segments; however, we have elected to disclose the results of these non-reportable operating segments. Our Internet of Things portfolio, presented as Internet of Things, is comprised of IOTG and Mobileye operating segments. In 2021, our DCG operating segment includes the results of our Intel ® Optane TM memory business, and our NSG operating segment is composed of our NAND memory business. Refer to "Note 8: Acquisitions and Divestitures" within Notes to Consolidated Condensed Financial Statements for further information on the pending divestiture of our NAND memory business. We have an “all other” category that includes revenue, expenses, and charges such as: ▪ results of operations from non-reportable segments not otherwise presented; ▪ historical results of operations from divested businesses; ▪ results of operations of start-up businesses that support our initiatives, including our foundry business; ▪ amounts included within restructuring and other charges; ▪ a portion of employee benefits, compensation, and other expenses not allocated to the operating segments; and ▪ acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill. The CODM, who is our CEO, does not evaluate operating segments using discrete asset information. Operating segments do not record inter-segment revenue. We do not allocate gains and losses from equity investments, interest and other income, or taxes to operating segments. Although the CODM uses operating income to evaluate the segments, operating costs included in one segment may benefit other segments. The accounting policies for segment reporting are the same as for Intel as a whole. Net revenue and operating income (loss) for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Net revenue: Client Computing Group Platform $ 8,954 $ 8,762 $ 27,968 $ 25,703 Adjacent 710 1,085 2,410 3,415 9,664 9,847 30,378 29,118 Data Center Group Platform 5,747 5,151 16,261 17,759 Adjacent 749 754 2,254 2,256 6,496 5,905 18,515 20,015 Internet of Things IOTG 1,042 677 2,940 2,230 Mobileye 326 234 1,030 634 1,368 911 3,970 2,864 Non-Volatile Memory Solutions Group 1,105 1,153 3,310 4,150 Programmable Solutions Group 478 411 1,450 1,431 All other 81 106 873 311 Total net revenue $ 19,192 $ 18,333 $ 58,496 $ 57,889 Operating income (loss): Client Computing Group $ 3,317 $ 3,554 $ 11,197 $ 10,621 Data Center Group 2,057 1,903 5,271 8,494 Internet of Things IOTG 276 61 775 374 Mobileye 105 47 361 131 381 108 1,136 505 Non-Volatile Memory Solutions Group 442 29 1,015 285 Programmable Solutions Group 76 40 246 217 All other (1,046) (575) (4,398) (2,328) Total operating income $ 5,227 $ 5,059 $ 14,467 $ 17,794 Disaggregated net revenue for each period was as follows: Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Platform revenue CCG desktop platform $ 2,983 $ 2,483 $ 8,262 $ 7,691 CCG notebook platform 5,953 6,275 19,655 17,976 CCG other platform 1 18 4 51 36 DCG platform 5,747 5,151 16,261 17,759 IOTG platform 948 595 2,679 2,008 15,649 14,508 46,908 45,470 Adjacent revenue 2 3,543 3,825 11,588 12,419 Total revenue $ 19,192 $ 18,333 $ 58,496 $ 57,889 1 Includes our tablet and service provider revenue. 2 Includes all of our non-platform products for CCG, DCG, and IOTG such as modem, Ethernet, and silicon photonics, as well as Mobileye, NSG, and PSG products, as well as revenue included in our "all other" category.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 25, 2021
Earnings Per Share [Abstract]
Earnings Per Share	Note 3 : Earnings Per Share We computed basic earnings per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period. Three Months Ended Nine Months Ended (In Millions, Except Per Share Amounts) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Net income available to common stockholders $ 6,823 $ 4,276 $ 15,245 $ 15,042 Weighted average shares of common stock outstanding—basic 4,061 4,188 4,055 4,233 Dilutive effect of employee equity incentive plans 25 23 34 36 Weighted average shares of common stock outstanding—diluted 4,086 4,211 4,089 4,269 Earnings per share—basic $ 1.68 $ 1.02 $ 3.76 $ 3.55 Earnings per share—diluted $ 1.67 $ 1.02 $ 3.73 $ 3.52 Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan.

Contract Liabilities

Contract Liabilities	9 Months Ended
	Sep. 25, 2021
Revenue from Contract with Customer [Abstract]
Contract Liabilities	Note 4 : Contract Liabilities Contract liabilities consist of prepayments received from customers on long-term prepaid supply agreements toward future product delivery and other revenue deferrals from regular ongoing business activity. Contract liabilities were $351 million as of September 25, 2021 ($1.9 billion as of December 26, 2020). The following table shows the changes in contract liability balances relating to long-term prepaid supply agreements during the first nine months of 2021: (In Millions) Prepaid supply agreements balance as of December 26, 2020 $ 1,625 Concession payment (950) Prepaids utilized (627) Prepaid supply agreements balance as of September 25, 2021 $ 48

Other Financial Statement Detai

Other Financial Statement Details	9 Months Ended
	Sep. 25, 2021
Other Financial Statement Details [Abstract]
Other Financial Statement Details	Note 5 : Other Financial Statement Details Inventories (In Millions) Sep 25, 2021 Dec 26, 2020 Raw materials $ 1,274 $ 908 Work in process 6,304 5,693 Finished goods 2,220 1,826 Total inventories $ 9,798 $ 8,427 Interest and Other, Net Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Interest income $ 37 $ 53 $ 111 $ 229 Interest expense (144) (160) (463) (481) Other, net 31 33 24 (164) Total interest and other, net $ (76) $ (74) $ (328) $ (416) Interest expense in the preceding table is net of $95 million of interest capitalized in the third quarter of 2021 and $288 million in the first nine months of 2021 ($81 million in the third quarter of 2020 and $251 million in the first nine months of 2020).

Restructuring and Other Charges

Restructuring and Other Charges	9 Months Ended
	Sep. 25, 2021
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges	Note 6 : Restructuring and Other Charges A restructuring program was approved in the first quarter of 2020 to further align our workforce with our continuing investments in the business and to execute the planned divestiture of Home Gateway Platform, a division of CCG. These actions are substantially complete as of September 25, 2021. Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Employee severance and benefit arrangements $ 21 $ (17) $ 43 $ 90 Litigation charges and other 16 (2) 2,267 54 Asset impairment charges 5 (6) 287 2 Total restructuring and other charges $ 42 $ (25) $ 2,597 $ 146 Litigation charges and other includes a charge of $2.2 billion in the first quarter of 2021 related to the VLSI litigation, which is recorded as a Corporate charge in the "all other" category presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements. Refer to "Note 13: Contingencies" within Notes to Consolidated Condensed Financial Statements for further information on legal proceedings related to the VLSI litigation. Asset impairment charges includes impairments related to the shutdown in the second quarter of 2021 of two of our non-strategic businesses, the results of which are included in the “all other” category presented in “Note 2: Operating Segments” within Notes to Consolidated Condensed Financial Statements. The goodwill related to these businesses was impaired, resulting in a charge of $237 million recognized in the second quarter of 2021 in the “all other” category along with other impairment charges related to these businesses.

Investments

Investments	9 Months Ended
	Sep. 25, 2021
Investments and Cash [Abstract]
Investments	Note 7 : Investments Debt Investments Trading Assets For trading assets still held at the reporting date we recorded net losses of $144 million in the third quarter of 2021 and $329 million in the first nine months of 2021 ($205 million of net gains in the third quarter of 2020 and $347 million of net gains in the first nine months of 2020). Net gains on the related derivatives were $156 million in the third quarter of 2021 and $346 million in the first nine months of 2021 ($163 million of net losses in the third quarter of 2020 and $334 million of net losses in the first nine months of 2020). Available-for-Sale Debt Investments Available-for-sale investments include corporate debt, government debt, and financial institution instruments. Government debt includes instruments such as non-U.S. government bonds and U.S. agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of September 25, 2021 and December 26, 2020, substantially all time deposits were issued by institutions outside the U.S. The adjusted cost of our available-for-sale investments was $10.8 billion as of September 25, 2021 and $7.8 billion as of December 26, 2020. The adjusted cost of our available-for-sale investments approximated the fair value for these periods. The fair value of available-for-sale debt investments, by contractual maturity, as of September 25, 2021, was as follows: (In Millions) Fair Value Due in 1 year or less $ 7,823 Due in 1–2 years 631 Due in 2–5 years 322 Due after 5 years — Instruments not due at a single maturity date 2,035 Total $ 10,811 Equity Investments (In Millions) Sep 25, 2021 Dec 26, 2020 Marketable equity securities $ 2,064 $ 1,830 Non-marketable equity securities 3,970 3,304 Equity method investments 16 18 Total $ 6,050 $ 5,152 The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Ongoing mark-to-market adjustments on marketable equity securities $ (192) $ (146) $ (345) $ (84) Observable price adjustments on non-marketable equity securities 79 5 702 142 Impairment charges (38) (40) (111) (233) Sale of equity investments and other¹ 1,858 237 2,124 387 Total gains (losses) on equity investments, net $ 1,707 $ 56 $ 2,370 $ 212 1 Sale of equity investments and other includes realized gains (losses) on sales of non-marketable equity investments, our share of equity method investees' gains (losses) and distributions, and initial fair value adjustments recorded upon a security becoming marketable. Gains and losses for our marketable and non-marketable equity securities for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Net gains (losses) recognized during the period on equity securities $ 346 $ 19 $ 883 $ 102 Less: Net (gains) losses recognized during the period on equity securities sold during the period (46) (12) (189) (87) Unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date $ 300 $ 7 $ 694 $ 15 Sale of equity investments and other during the third quarter of 2021 includes $447 million of initial fair value adjustments related to four companies that went public, and a McAfee special dividend of $1.1 billion paid in connection with the sale of McAfee's Enterprise Business to Symphony Technology Group. Beijing Unisoc Technology Ltd. We account for our interest in Beijing Unisoc Technology Ltd. (Unisoc) as a non-marketable equity security. In the first quarter of 2021, we recognized $471 million in observable price adjustments in our investment in Unisoc and as of September 25, 2021, the net book value of the investment was $1.1 billion ($658 million as of December 26, 2020).

Acquisitions and Divestitures

Acquisitions and Divestitures	9 Months Ended
	Sep. 25, 2021
Business Combinations [Abstract]
Acquisitions and Divestitures	Note 8 : Acquisitions and Divestitures Acquisitions On May 4, 2020, we acquired Moovit, a MaaS solutions company , for total consideration of $915 million. The fair values of the assets acquired relate to goodwill of $638 million and intangible assets of $331 million . The goodwill arising from the acquisition is attributed to the expected synergies and other benefits that will be generated from the combination of Intel and Moovit . S ubstantially all of the goodwill will not be deductible for local tax purposes. The acquisition-related intangible assets are primarily related to Moovit's monthly active user base and application platform . The goodwill and operating results of Moovit are included in our Mobileye operating segment. Divestitures NAND Memory Business On October 19, 2020, we signed an agreement with SK hynix Inc. (SK hynix) to divest our NAND memory business, including our NAND memory fabrication facility in Dalian, China and certain related equipment and tangible assets (the Fab Assets), our NAND SSD business (the NAND SSD Business), and our NAND memory technology and manufacturing business (the NAND OpCo Business). Our Intel Optane memory business is expressly excluded from the transaction. The transaction will occur over two closings for total consideration of $9.0 billion in cash, of which $7.0 billion will be received upon initial closing, not to occur prior to November 1, 2021, and the remaining $2.0 billion will be received no earlier than March 2025. The consummations of the first closing and the second closing are subject to customary conditions, including the receipt of certain governmental approvals. At the first closing, Intel will sell to SK hynix the Fab Assets and the NAND SSD Business, and SK hynix will assume from Intel certain liabilities related to the Fab Assets and the NAND SSD Business. In connection with the first closing, we and certain affiliates of SK hynix will also enter into a NAND wafer manufacturing and sale agreement pursuant to which we will manufacture and sell to SK hynix NAND memory wafers to be manufactured using the Fab Assets in Dalian, China, until the second closing. We will transfer certain employees, IP, and other assets related to the NAND OpCo Business to separately created, wholly owned subsidiaries of Intel at the first closing. The equity interest of these wholly owned subsidiaries will transfer to SK hynix at the second closing. We have concluded based on the terms of the transaction agreements that the subsidiaries will be variable interest entities for which we are not the primary beneficiary, and accordingly will deconsolidate at the first closing. The carrying amounts of the major classes of NAND assets held for sale included the following: (In Millions) Sep 25, 2021 Dec 26, 2020 Inventories $ 804 $ 962 Property, plant and equipment, net 5,594 4,363 Total assets held for sale $ 6,398 $ 5,325 We ceased recording depreciation on property, plant and equipment as of the date the assets triggered held for sale accounting. The agreement provides for total capital purchases of approximately $1.8 billion in 2021 and amounts prior to the first closing will be classified as assets held for sale in the Consolidated Condensed Balance Sheets and within additions to held for sale NAND property, plant and equipment on the Consolidated Condensed Statements of Cash Flows.

Borrowings

Borrowings	9 Months Ended
	Sep. 25, 2021
Debt Disclosure [Abstract]
Borrowings	Note 9 : Borrowings As of September 25, 2021, our short-term debt was $4.7 billion, primarily comprised of the current portion of our long-term debt ($2.5 billion as of December 26, 2020). In the second quarter of 2021, we settled $500 million of our senior notes due May 2021. In the third quarter of 2021, we issued a total of $5.0 billion aggregate principal senior notes. We intend to use the proceeds from the offering of the notes for general corporate purposes, including, but not limited to, refinancing of outstanding debt, funding for working capital, and capital expenditures. In the first quarter of 2021, we entered into a $5.0 billion variable-rate revolving credit facility which, if drawn, is expected to be used for general corporate purposes. The revolving credit facility matures in March 2026 and had no borrowings outstanding as of September 25, 2021. We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. Our senior floating rate notes pay interest quarterly and our senior fixed rate notes pay interest semiannually. We may redeem the fixed rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under our notes rank equally in right of payment with all of our other existing and future senior unsecured indebtedness and effectively rank junior to all liabilities of our subsidiaries. Long-term Debt Sep 25, 2021 Dec 26, 2020 (In Millions) Effective Interest Rate Amount Amount Floating-rate senior notes: Three-month LIBOR plus 0.35%, due May 2022 0.56 % $ 800 $ 800 Fixed-rate senior notes: 1.70%, due May 2021 — % — 500 3.30%, due October 2021 2.98 % 2,000 2,000 2.35%, due May 2022 1.96 % 750 750 3.10%, due July 2022 2.70 % 1,000 1,000 4.00%, due December 2022¹ 2.95 % 400 417 2.70%, due December 2022 2.28 % 1,500 1,500 4.10%, due November 2023 3.22 % 400 400 2.88%, due May 2024 2.31 % 1,250 1,250 2.70%, due June 2024 2.14 % 600 600 3.40%, due March 2025 3.45 % 1,500 1,500 3.70%, due July 2025 2.16 % 2,250 2,250 2.60%, due May 2026 0.64 % 1,000 1,000 3.75%, due March 2027 3.79 % 1,000 1,000 3.15%, due May 2027 1.22 % 1,000 1,000 1.60%, due August 2028 1.68 % 1,000 — 2.45%, due November 2029 2.39 % 2,000 2,000 3.90%, due March 2030 3.92 % 1,500 1,500 2.00%, due August 2031 2.04 % 1,250 — 4.00%, due December 2032 1.25 % 750 750 4.60%, due March 2040 4.60 % 750 750 2.80%, due August 2041 2.82 % 750 — 4.80%, due October 2041 2.02 % 802 802 4.25%, due December 2042 1.42 % 567 567 4.90%, due July 2045 2.12 % 772 772 4.10%, due May 2046 1.41 % 1,250 1,250 4.10%, due May 2047 1.37 % 1,000 1,000 4.10%, due August 2047 0.92 % 640 640 3.73%, due December 2047 1.77 % 1,967 1,967 3.25%, due November 2049 3.19 % 2,000 2,000 4.75%, due March 2050 4.74 % 2,250 2,250 3.05%, due August 2051 3.07 % 1,250 — 3.10%, due February 2060 3.11 % 1,000 1,000 4.95%, due March 2060 4.99 % 1,000 1,000 3.20%, due August 2061 3.22 % 750 — Oregon and Arizona bonds: 2.40%-2.70%, due December 2035 - 2040 2.49 % 423 423 5.00%, due March 2049 2.12 % 138 138 5.00%, due June 2049 2.15 % 438 438 Total Senior Notes and Other Borrowings 39,697 35,214 Unamortized premium/discount and issuance costs (402) (378) Hedge accounting fair value adjustments 1,009 1,565 Long-term debt 40,304 36,401 Current portion of long-term debt (4,694) (2,504) Total long-term debt $ 35,610 $ 33,897 1 To manage foreign currency risk associated with the Australian-dollar-denominated notes issued in 2015, we entered into currency interest rate swaps with an aggregate notional amount of $396 million, which effectively converted these notes to U.S.-dollar-denominated notes. For further discussion on derivatives in cash flow hedging relationships, see "Note 12: Derivative Financial Instruments."

Fair Value

Fair Value	9 Months Ended
	Sep. 25, 2021
Fair Value Disclosures [Abstract]
Fair Value	Note 10 : Fair Value Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Sep 25, 2021 Dec 26, 2020 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 736 $ — $ 736 $ — $ 50 $ — $ 50 Financial institution instruments¹ 2,035 718 — 2,753 2,781 636 — 3,417 Government debt² 2,200 164 — 2,364 — — — — Reverse repurchase agreements — 1,350 — 1,350 — 1,900 — 1,900 Short-term investments: Corporate debt — 870 — 870 — 428 — 428 Financial institution instruments¹ — 2,066 — 2,066 — 1,179 — 1,179 Government debt² — 1,068 — 1,068 — 685 — 685 Trading assets: Corporate debt — 5,121 — 5,121 — 3,815 — 3,815 Financial institution instruments¹ 67 4,014 — 4,081 131 2,847 — 2,978 Government debt² — 13,559 — 13,559 — 8,945 — 8,945 Other current assets: Derivative assets 4 323 — 327 48 644 — 692 Loans receivable³ — 211 — 211 — 439 — 439 Marketable equity securities 272 1,792 — 2,064 136 1,694 — 1,830 Other long-term investments: Corporate debt — 684 — 684 — 1,520 — 1,520 Financial institution instruments¹ — 203 — 203 — 257 — 257 Government debt² — 66 — 66 — 415 — 415 Other long-term assets: Derivative assets — 961 13 974 — 1,520 30 1,550 Loans receivable³ — — — — — 157 — 157 Total assets measured and recorded at fair value $ 4,578 $ 33,906 $ 13 $ 38,497 $ 3,096 $ 27,131 $ 30 $ 30,257 Liabilities Other accrued liabilities: Derivative liabilities $ 29 $ 527 $ — $ 556 $ — $ 810 $ — $ 810 Other long-term liabilities: Derivative liabilities — 9 — 9 — 5 — 5 Total liabilities measured and recorded at fair value $ 29 $ 536 $ — $ 565 $ — $ 815 $ — $ 815 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of commercial paper, certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 1 investments consist primarily of U.S. Treasury securities. Level 2 investments consist primarily of U.S. agency notes and non-U.S. government debt. 3 The fair value of our loans receivable for which we elected the fair value option did not significantly differ from the contractual principal balance. Assets Measured and Recorded at Fair Value on a Non-Recurring Basis Our non-marketable equity securities, equity method investments, and certain non-financial assets, such as intangible assets and property, plant and equipment, are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, and issued debt. We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of September 25, 2021 was $399 million (the aggregate carrying value of grants receivable as of December 26, 2020 was $139 million).

Other Comprehensive Income (Los

Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 25, 2021
Equity [Abstract]
Other Comprehensive Income (Loss)	Note 11 : Other Comprehensive Income (Loss) The changes in accumulated other comprehensive income (loss) by component and related tax effects in the first nine months of 2021 were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total Balance as of December 26, 2020 $ 731 $ (1,565) $ 83 $ (751) Other comprehensive income (loss) before reclassifications (313) 5 (41) (349) Amounts reclassified out of accumulated other comprehensive income (loss) (196) 47 (14) (163) Tax effects 119 (14) 11 116 Other comprehensive income (loss) (390) 38 (44) (396) Balance as of September 25, 2021 $ 341 $ (1,527) $ 39 $ (1,147)

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 25, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 12 : Derivative Financial Instruments Volume of Derivative Activity Total gross notional amounts for outstanding derivatives at the end of each period were as follows: (In Millions) Sep 25, 2021 Dec 26, 2020 Foreign currency contracts $ 35,012 $ 31,209 Interest rate contracts 14,960 14,461 Other 2,419 2,026 Total $ 52,391 $ 47,696 Fair Value of Derivative Instruments Sep 25, 2021 Dec 26, 2020 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 99 $ 74 $ 551 $ 2 Interest rate contracts 966 — 1,498 — Total derivatives designated as hedging instruments 1,065 74 2,049 2 Derivatives not designated as hedging instruments: Foreign currency contracts 3 221 378 142 685 Interest rate contracts 11 84 3 128 Equity contracts 4 29 48 — Total derivatives not designated as hedging instruments 236 491 193 813 Total derivatives $ 1,301 $ 565 $ 2,242 $ 815 1 Derivative assets are recorded as other assets, current and non-current. 2 Derivative liabilities are recorded as other liabilities, current and non-current. 3 The majority of these instruments mature within 12 months. Amounts Offset in the Consolidated Condensed Balance Sheets The gross amounts of our derivative instruments and reverse repurchase agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 25, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,295 $ — $ 1,295 $ (329) $ (913) $ 53 Reverse repurchase agreements 1,350 — 1,350 — (1,350) — Total assets 2,645 — 2,645 (329) (2,263) 53 Liabilities: Derivative liabilities subject to master netting arrangements 408 — 408 (329) (79) — Total liabilities $ 408 $ — $ 408 $ (329) $ (79) $ — Dec 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master netting arrangements 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ — We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate. Derivatives in Cash Flow Hedging Relationships The before-tax net gains or losses attributed to cash flow hedges, recognized in other comprehensive income (loss), were $28 million net losses in the third quarter of 2021 and $313 million net losses in the first nine months of 2021 ($267 million net gains in the third quarter of 2020 and $286 million net gains in the first nine months of 2020). Substantially all of our cash flow hedges were foreign currency contracts for all periods presented. During the first nine months of 2021 and 2020, the amounts excluded from effectiveness testing were insignificant. Derivatives in Fair Value Hedging Relationships The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) Recognized in Consolidated Condensed Statements of Income on Derivatives Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Interest rate contracts $ (55) $ (36) $ (532) $ 996 Hedged items 55 36 532 (996) Total $ — $ — $ — $ — The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheet in Which the Hedged Item is Included Carrying Amount of the Hedged Item Asset/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Sep 25, 2021 Dec 26, 2020 Sep 25, 2021 Dec 26, 2020 Long-term debt $ (12,963) $ (13,495) $ (966) $ (1,498) The total notional amount of pay-variable and receive-fixed interest rate swaps was $12.0 billion as of September 25, 2021 and $12.0 billion as of December 26, 2020. Derivatives Not Designated as Hedging Instruments The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Location of Gains (Losses) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Foreign currency contracts Interest and other, net $ 170 $ (166) $ 382 $ (228) Interest rate contracts Interest and other, net (7) (3) 14 (94) Other Various 84 138 279 95 Total $ 247 $ (31) $ 675 $ (227)

Contingencies

Contingencies	9 Months Ended
	Sep. 25, 2021
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 13 : Contingencies Legal Proceedings We are a party to various legal proceedings, including those noted in this section. In the first quarter of 2021, we accrued a charge of $2.2 billion related to litigation involving VLSI, described below. Excluding this charge, management at present believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, results of operations, cash flows, or overall trends; however, legal proceedings and related government investigations are subject to inherent uncertainties, and unfavorable rulings or other events could occur. Unfavorable resolutions could include substantial monetary damages. In addition, in matters for which injunctive relief or other conduct remedies are sought, unfavorable resolutions could include an injunction or other order prohibiting us from selling one or more products at all or in particular ways, precluding particular business practices, or requiring other remedies. An unfavorable outcome may result in a material adverse impact on our business, results of operations, financial position, and overall trends. We might also conclude that settling one or more such matters is in the best interests of our stockholders, employees, and customers, and any such settlement could include substantial payments. Except as specifically described below, we have not concluded that settlement of any of the legal proceedings noted in this section is appropriate at this time. European Commission Competition Matter In 2001, the EC commenced an investigation regarding claims by Advanced Micro Devices, Inc. (AMD) that we used unfair business practices to persuade customers to buy our microprocessors. We received numerous requests for information and documents from the EC and we responded to each of those requests. The EC issued a Statement of Objections in July 2007 and held a hearing on that Statement in March 2008. The EC issued a Supplemental Statement of Objections in July 2008. In May 2009, the EC issued a decision finding that we had violated Article 82 of the EC Treaty and Article 54 of the European Economic Area Agreement. In general, the EC found that we violated Article 82 (later renumbered as Article 102 by a new treaty) by offering alleged "conditional rebates and payments" that required our customers to purchase all or most of their x86 microprocessors from us. The EC also found that we violated Article 82 by making alleged "payments to prevent sales of specific rival products." The EC imposed a fine in the amount of €1.1 billion ($1.4 billion as of May 2009), which we subsequently paid during the third quarter of 2009, and ordered us to "immediately bring to an end the infringement referred to in" the EC decision. The EC decision contained no specific direction on whether or how we should modify our business practices. Instead, the decision stated that we should "cease and desist" from further conduct that, in the EC's opinion, would violate applicable law. We took steps, which are subject to the EC's ongoing review, to comply with that decision pending appeal. We had discussions with the EC to better understand the decision and to explain changes to our business practices. We appealed the EC decision to the Court of First Instance (which has been renamed the General Court) in July 2009. The hearing of our appeal took place in July 2012. In June 2014, the General Court rejected our appeal in its entirety. In August 2014, we filed an appeal with the European Court of Justice. In November 2014, Intervener Association for Competitive Technologies filed comments in support of Intel’s grounds of appeal. The EC and interveners filed briefs in November 2014, we filed a reply in February 2015, and the EC filed a rejoinder in April 2015. The Court of Justice held oral argument in June 2016. In October 2016, Advocate General Wahl, an advisor to the Court of Justice, issued a non-binding advisory opinion that favored Intel on a number of grounds. The Court of Justice issued its decision in September 2017, setting aside the judgment of the General Court and sending the case back to the General Court to examine whether the rebates at issue were capable of restricting competition. The General Court has appointed a panel of five judges to consider our appeal of the EC’s 2009 decision in light of the Court of Justice’s clarifications of the law. In November 2017, the parties filed initial “Observations” about the Court of Justice’s decision and the appeal and were invited by the General Court to offer supplemental comments to each other’s “Observations,” which the parties submitted in March 2018. Responses to other questions posed by the General Court were filed in May and June 2018. The General Court heard oral argument in March 2020. Pending the final decision in this matter, the fine paid by Intel has been placed by the EC in commercial bank accounts where it accrues interest. Litigation Related to Security Vulnerabilities In June 2017, a Google research team notified us and other companies that it had identified security vulnerabilities (now commonly referred to as “Spectre” and “Meltdown”) that affect many types of microprocessors, including our products. As is standard when findings like these are presented, we worked together with other companies in the industry to verify the research and develop and validate software and firmware updates for impacted technologies. On January 3, 2018, information on the security vulnerabilities was publicly reported, before software and firmware updates to address the vulnerabilities were made widely available. Numerous lawsuits have been filed against Intel and, in certain cases, our current and former executives and directors, in U.S. federal and state courts and in certain courts in other countries relating to the Spectre and Meltdown security vulnerabilities, as well as other variants of these vulnerabilities that have since been identified. As of October 20, 2021, consumer class action lawsuits relating to the above class of security vulnerabilities publicly disclosed since 2018 were pending in the United States, Canada, and Israel. The plaintiffs, who purport to represent various classes of purchasers of our products, generally claim to have been harmed by Intel's actions and/or omissions in connection with the security vulnerabilities and assert a variety of common law and statutory claims seeking monetary damages and equitable relief. In the United States, numerous individual class action suits filed in various jurisdictions were consolidated in April 2018 for all pretrial proceedings in the U.S. District Court for the District of Oregon. In March 2020, the court granted Intel's motion to dismiss the complaint in that consolidated action but granted plaintiffs leave to amend. In March 2021, the court granted Intel’s motion to dismiss the amended complaint, but granted plaintiffs leave to further amend in part. Plaintiffs filed a further amended complaint in May 2021 which Intel moved to dismiss in July 2021. In Canada, in one case pending in the Superior Court of Justice of Ontario, an initial status conference has not yet been scheduled. In a second case pending in the Superior Court of Justice of Quebec, a stay of the case is in effect until December 2021. In Israel, two consumer class action lawsuits were filed in the District Court of Haifa. The plaintiff voluntarily dismissed the first lawsuit in July 2021. Intel filed a motion to stay the second case pending resolution of the consolidated proceeding in the United States, and a hearing on that motion has been scheduled for April 2022. Additional lawsuits and claims may be asserted seeking monetary damages or other related relief. We dispute the pending claims described above and intend to defend those lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters. In addition to these lawsuits, Intel stockholders filed multiple shareholder derivative lawsuits since January 2018 against certain current and former members of our Board of Directors and certain current and former officers, alleging that the defendants breached their duties to Intel in connection with the disclosure of the security vulnerabilities and the failure to take action in relation to alleged insider trading. The complaints sought to recover damages from the defendants on behalf of Intel. Some of the derivative actions were filed in the U.S. District Court for the Northern District of California and were consolidated, and the others were filed in the Superior Court of the State of California in San Mateo County and were consolidated. The federal court granted defendants' motion to dismiss in August 2018 on the ground that plaintiffs failed to plead facts sufficient to show they were excused from making a pre-lawsuit demand on the Board. The federal court granted plaintiffs leave to amend their complaint, but subsequently dismissed the cases in January 2019 at plaintiffs' request. The California Superior Court entered judgment in defendants' favor in August 2020 after granting defendants' motions to dismiss plaintiffs' consolidated complaint and three successive amended complaints, all for failure to plead facts sufficient to show plaintiffs were excused from making pre-lawsuit demand on the Board. Plaintiffs filed a notice of appeal of the California court's judgment in October 2020. In January 2021, another Intel stockholder filed a derivative lawsuit in the Superior Court in San Mateo County against certain current and former officers and members of our Board of Directors. The lawsuit asserts claims similar to those dismissed in August 2020, except that it alleges that the stockholder made a pre-lawsuit demand on our Board of Directors and that the demand was wrongfully refused. In May 2021, the court granted defendants' motion to stay the action pending the outcome of any litigation plaintiff may choose to file in Delaware where Intel’s bylaws require such claims be filed. Institute of Microelectronics, Chinese Academy of Sciences v. Intel China, Ltd., et al. In February 2018, the Institute of Microelectronics of the Chinese Academy of Sciences (IMECAS) sued Intel China, Ltd., Dell China, Ltd. (Dell), and Beijing JingDong Century Information Technology, Ltd. (JD) for patent infringement in the Beijing Higher People's Court. IMECAS alleges that Intel’s Core series processors infringe Chinese patent CN 102956457 (’457 Patent). The complaint demands an injunction and damages of at least RMB 200 million plus the cost of litigation. In March 2018, Dell tendered indemnity to Intel, which Intel granted in April 2018. JD also tendered indemnity to Intel, which Intel granted in October 2018. The Beijing Higher People’s Court held a final trial hearing in September 2021. No ruling has been issued. In March 2018, Intel filed an invalidation request on the ‘457 patent with the China National Intellectual Property Administration (CNIPA). The CNIPA held an oral hearing in September 2018 and in February 2019 upheld the validity of the challenged claims. Intel filed a complaint in April 2019 with the Beijing Intellectual Property Court challenging the February 2019 CNIPA ruling, and the Beijing IP Court held oral arguments in July 2021. In January 2020, Intel filed a second invalidation request on the ‘457 patent with the CNIPA, for which the CNIPA heard oral argument in July 2020 and in November 2020 held the challenged apparatus claims invalid. IMECAS filed a complaint in February 2021 with the Beijing IP Court challenging the November 2020 CNIPA ruling. In December 2020, Intel filed a third invalidation request on the ’457 patent with the CNIPA, which heard oral argument in June 2021 and issued a ruling in September 2021 holding the challenged claims not invalid. In September 2018 and March 2019, Intel filed petitions with the U.S. Patent & Trademark Office (USPTO) requesting institution of inter partes review (IPR) of U.S. Patent No. 9,070,719, the U.S. counterpart to the ‘457 patent. The USPTO denied institution of Intel’s petitions in March and October 2019, respectively. In April 2019, Intel filed a request for rehearing and a petition for a Precedential Opinion Panel (POP) in the USPTO to challenge the denial of its first IPR petition, and in November 2019 Intel filed a request for rehearing on the second IPR petition. In January 2020, the USPTO denied the POP petition on the first IPR petition. In June 2020, the Patent Trial and Appeal Board denied Intel's rehearing requests on both petitions. In October 2019, IMECAS filed second and third lawsuits, in the Beijing IP Court, alleging infringement of Chinese Patent No. CN 102386226 (‘226 Patent) based on the manufacturing and sale of Intel’s Core i3 microprocessors. Defendants in the second case are Lenovo (Beijing) Co., Ltd. (Lenovo) and Beijing Jiayun Huitong Technology Development Co. Ltd. (BJHT). Defendants in the third case are Intel Corp., Intel China Co., Ltd., the Intel China Beijing Branch, Beijing Digital China Co., Ltd. (Digital China), and JD. Both complaints demand injunctions plus litigation costs. The complaint in the second lawsuit reserves the right to claim damages in unspecified amounts. The complaint in the third lawsuit claims damages of RMB 10 million. Intel China's jurisdictional challenge was denied in June 2021. No trial proceedings have occurred or are yet scheduled in these lawsuits. In December 2019, Lenovo tendered indemnity to Intel, which Intel granted in March 2020. In July 2020, Intel and Lenovo filed invalidation requests on the '226 patent with the CNIPA. The CNIPA heard oral argument in December 2020, during which IMECAS proposed amendments to two claims. The CNIPA ruled in April 2021 on both invalidation requests, finding the two amended claims as well as the unamended claims not invalid. Intel and Lenovo filed complaints in July 2021 with the Beijing IP Court challenging the April 2021 CNIPA rulings. Given the procedural posture and the nature of these cases, the unspecified nature and extent of damages claimed by IMECAS, and uncertainty regarding the availability of injunctive relief under applicable law, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, arising from these matters. We dispute IMECAS’s claims and intend to vigorously defend against them. VLSI Technology LLC v. Intel In October 2017, VLSI filed a complaint against Intel in the U.S. District Court for the Northern District of California alleging infringement of eight patents acquired from NXP Semiconductors, N.V. (NXP). The patents, which originated at Freescale Semiconductor, Inc. and NXP B.V., are U.S. Patent Nos. 7,268,588; 7,675,806; 7,706,207; 7,709,303; 8,004,922; 8,020,014; 8,268,672; and 8,566,836. VLSI accuses various FPGA and processor products of infringement. VLSI estimated its damages to be as high as $7.1 billion, and its complaint further sought enhanced damages, future royalties, attorneys’ fees, costs, and interest. In May, June, September, and October 2018, Intel filed IPR petitions challenging the patentability of certain claims in all eight of the patents in-suit. The PTAB instituted review of six patents and denied institution on two patents. As a result of the institution decisions, the parties stipulated to stay the District Court action in March 2019. In December 2019 and February 2020, the PTAB found all claims of the '588 and '303 patents, and some claims of the '922 patent, to be unpatentable. The PTAB found the challenged claims of the '014, '672, and '207 patents to be patentable. Intel moved for a continuation of the stay in March 2020 as it appealed certain rulings by the PTAB. In June 2020, the District Court issued an order continuing the stay through August 2021 and setting trial for December 2022. The Federal Circuit has thus far affirmed the PTAB’s decisions as to the ‘207 and ‘672 patents, and reversed the PTAB’s decision as to the ‘014 patent. The court lifted the stay in September 2021. In June 2018, VLSI filed a second suit against Intel, in U.S. District Court for the District of Delaware, alleging infringement by various Intel processors of five additional patents acquired from NXP: U.S. Patent Nos. 6,212,663; 7,246,027; 7,247,552; 7,523,331; and 8,081,026. VLSI accused Intel of willful infringement and seeks an injunction or, in the alternative, ongoing royalties, enhanced damages, attorneys’ fees and costs, and interest. In March 2019, the District Court dismissed VLSI’s claims for willful infringement as to all the patents-in-suit except the ‘027 patent, and also dismissed VLSI’s allegations of indirect infringement as to the ‘633, ‘331, and ‘026 patents. In June 2019, Intel filed requests for inter partes review of the patentability of claims in all five patents-in-suit. In January 2020, the District Court vacated an earlier November 2020 trial date based on agreement of the parties; no trial date is currently set. In January 2020, VLSI said that it was no longer asserting any claims of the ‘633 patent. In January and February 2020, the PTAB instituted review of the '552, '633, '331, and '026 patents, but declined to institute review on the '027 patent. As a result, Intel moved for stay of the District Court proceedings. In May 2020, the District Court stayed the case as to the '026 and '552 patents but allowed the case to proceed on the '027 and '331 patents. In January 2021, the PTAB invalidated certain asserted claims of the ‘026 patent, and in February the PTAB invalidated all asserted claims of the ‘552 patent. Intel filed a notice of appeal regarding the PTAB’s decision as to the ‘026 patent in March 2021, and the case remains stayed as to that patent and the '552 patent. For the '027 and '331 patents, VLSI is seeking damages of approximately $4.13 billion plus enhanced damages for the '027 patent. The deadline to file summary judgment motions and challenges to expert witnesses is in January 2022. In March 2019, VLSI filed a third suit against Intel, also in U.S. District Court for the District of Delaware, alleging infringement of six more patents acquired from NXP: U.S. Patent Nos. 6,366,522; 6,663,187; 7,292,485; 7,606,983; 7,725,759; and 7,793,025. In April 2019, VLSI voluntarily dismissed this Delaware case without prejudice. In April 2019, VLSI filed three new infringement suits against Intel in the U.S. District Court for the Western District of Texas (WDTX) accusing various Intel processors of infringement. The three suits collectively assert the same six patents from the voluntarily dismissed Delaware case plus two additional patents acquired from NXP, U.S. Patent Nos. 7,523,373 and 8,156,357. VLSI accuses Intel of willful infringement and seeks an injunction or, in the alternative, ongoing royalties, enhanced damages, attorneys’ fees and costs, and interest. In the first Texas case, VLSI asserted the ‘373 and ‘759 patents (in December 2020 the court granted Intel summary judgment of non-infringement on the ‘357 patent, which had also been asserted in the first Texas case). That case went to trial in February 2021, and the jury awarded a “lump sum” to VLSI of $1.5 billion for literal infringement of the ‘373 patent and $675 million for infringement under the doctrine of equivalents of the ‘759 patent. The jury found that Intel had not willfully infringed either patent. Intel plans to challenge the verdict in post-trial motions and on appeal. Intel has challenged the verdict with post-trial motions, including filing in May 2021 a motion for a new trial and a motion for judgment as a matter of law that the ‘373 and ‘759 patents are not infringed and the ‘759 patent is invalid. The court denied the motion for new trial in August 2021, but other post-trial motions, including the motion for judgment as a matter of law, remain pending. If the court does not vacate the verdict Intel will challenge it on appeal. The second Texas case went to trial in April 2021, and the jury found that Intel does not infringe the ‘522 and ‘187 patents. VLSI had sought approximately $3 billion for alleged infringement of those patents, plus enhanced damages for willful infringement. The third case is scheduled for trial in December 2021, and VLSI seeks approximately $2.2 billion to $2.4 billion for alleged infringement of the ‘983, ‘025 and ‘485 patents, plus enhanced damages for willful infringement. In October and November 2019, and in February 2020, Intel filed IPR petitions on certain asserted claims across six of the patents-in-suit in WDTX. Between May and October 2020, the PTAB denied all of these requests and Intel requested a rehearing, as well as review from the POP as to all petitions. All requests for POP review were denied in October and December 2020, and all requests for rehearing were denied as to all petitions between December 2020 and February 2021. Intel filed notices of appeal regarding the discretionary denials for all petitions in February and March of 2021, and VLSI moved to dismiss those appeals in March 2021. The Court dismissed the appeals in May 2021, and Intel petitioned for hearing en banc in June 2021. The Federal Circuit denied the petition in August 2021. In May 2019, VLSI filed a case in Shenzhen Intermediate People’s Court against Intel, Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserts Chinese Patent 201410094015.9 accusing certain Intel Core processors of infringement. VLSI requests an injunction as well as RMB 1 million in damages and RMB 300 thousand in expenses. Defendants filed an invalidation petition in October 2019 with the CNIPA, which held a hearing in September 2021. In May 2020, defendants filed a motion to stay the trial court proceedings pending a determination on invalidity. The court held the first evidentiary hearing in November 2020 and the second in July 2021. The court also held trial proceedings in the hearing in July 2021 and concluded that further trial proceedings were needed but would be stayed pending the outcome of defendants’ invalidity challenge at the CNIPA. In May 2019, VLSI filed a second case in Shanghai Intellectual Property Court against Intel (China) Co., Ltd., Intel Trading (Shanghai) Co., Ltd., and Intel Products (Chengdu) Co., Ltd. VLSI asserts Chinese Patent 201080024173.7. VLSI accuses certain Intel Core processors and seeks an injunction, as well as RMB 1 million in damages and RMB 300 thousand in expenses. Defendants filed with the CNIPA an invalidation petition in October 2019, and the CNIPA held a hearing in September 2021, but has not yet issued a decision. In June 2020, defendants filed a motion to stay the trial court proceedings pending a determination on invalidity. The court held its first evidentiary hearing in September 2020. The court held a second evidentiary hearing in December 2020, and a trial the same month. At trial, VLSI dropped its monetary damages claim, but still requested expenses (RMB 300 thousand) and an injunction. The court held a second evidentiary hearing in December 2020. The court has not yet issued a decision following the trial. Rather, the court stayed the case in December 2020 pending a determination on invalidity by the CNIPA. In November 2019, Intel, along with Apple Inc., filed a complaint against Fortress Investment Group LLC, Fortress Credit Co. LLC, Uniloc 2017 LLC, Uniloc USA, Inc., Uniloc Luxembourg S.A.R.L., VLSI, INVT SPE LLC, Inventergy Global, Inc., DSS Technology Management, Inc., IXI IP, LLC, and Seven Networks, LLC. Plaintiffs allege violations of Section 1 of the Sherman Act by certain defendants, Section 7 of the Clayton Act by certain defendants, and California Business and Professions Code section 17200 by all defendants based on defendants' unlawful aggregation of patents. In February 2020, defendants moved to dismiss plaintiffs' complaint. In July 2020, the court granted defendants’ motion to dismiss with leave to amend. The court dismissed antitrust claims related to two DSS patents with prejudice. The plaintiffs filed an amended complaint in August 2020, and defendants moved to dismiss in September 2020. The court heard defendants' motion to dismiss the amended complaint in December 2020 and dismissed plaintiffs’ amended complaint in January 2021, with leave to further amend. In December 2020, the court granted a joint motion by Apple and Seven Networks to dismiss with prejudice Apple’s claims against Seven Networks. Plaintiffs filed a second amended complaint in March 2021. Defendants moved to dismiss the Second Amended Complaint in May 2021. Apple withdrew from the case and dismissed its claims in June 2021. The court heard defendants’ motion to dismiss the Second Amended Complaint in September 2021, and dismissed Intel’s claims with prejudice that same month, entering judgment in favor of defendants. In June 2020, affiliates controlled by Fortress Investment Group, which also controls VLSI, acquired Finjan Holdings, Inc. Intel had signed a “Settlement, Release and Patent License Agreement” with Finjan in 2012, acquiring a license to the patents of Finjan and its affiliates, current or future, through a capture period of November 20, 2022. The agreement also contains covenants wherein Finjan agrees to cause its affiliates to comply with the agreement. As such, Intel maintains that it now has a license to the patents of VLSI, which has become a Finjan affiliate, and that Finjan must cause VLSI to dismiss its suits against Intel. In August 2020, Intel started dispute resolution proceedings under the agreement. As a part of this dispute resolution process, Intel and Finjan held a mediation in December 2020, but failed to resolve their differences. Intel filed suit to enforce its rights under the License Agreement with Finjan in January 2021 in Delaware Chancery Court. In March 2021, defendants filed motions to dismiss the Chancery Court proceedings. The court heard those motions in May 2021, and dismissed all of Intel’s claims—except the breach of contract claim—with prejudice in September 2021 for lack of jurisdiction because, the court reasoned, Intel’s license defense has been raised in the other U.S. suits between Intel and VLSI and could be adjudicated in one of those actions. The court stayed Intel’s breach of contract claim pending a determination on whether Intel is licensed to VLSI’s patents. In September 2020, Intel filed motions to stay the Texas, Delaware, and Shanghai matters pending resolution of its dispute with Finjan. In November 2020, Intel filed a motion to stay the Shenzhen matter pending resolution of its dispute with Finjan. In November 2020, the Delaware court denied Intel’s motion to stay. The other stay motions remain pending. Finally, Intel filed a motion to amend its answer in the Texas matters to add a license defense in November 2020, and filed a motion to amend its answer in the Delaware matter to add a license defense in February 2021. The Texas court has not yet ruled on Intel’s motion to amend, but the Delaware court granted Intel’s motion in July 2021. After consideration of the verdicts in the WDTX cases and the additional pending lawsuits filed by VLSI, Intel accrued a charge of $2.2 billion in the first quarter of 2021. We dispute VLSI’s claims and intend to vigorously defend against them. Litigation Related to 7nm Product Delay Announcement Starting in July 2020, five securities class action lawsuits were filed in the U.S. District Court for the Northern District of California against Intel and certain current and former officers based on Intel’s July 2020 announcement of 7nm product delays. The plaintiffs, who purport to represent classes of acquirers of Intel stock between October 2019 and July 2020, generally allege that the defendants violated securities laws by making false or misleading statements about the timeline for 7nm products in light of subsequently announced delays. In October 2020, the court consolidated the lawsuits and appointed lead plaintiffs, and in January 2021 the lead plaintiffs filed a consolidated complaint. Defendants moved to dismiss the consolidated complaint in March 2021. We dispute the claims described above and intend to defend the lawsuits vigorously. Given the procedural posture and the nature of those cases, including that the pending proceedings are in the early stages, that alleged damages have not been specified, that uncertainty exists as to the likelihood of a class or classes being certified or the ultimate size of any class or classes if certified, and that there are significant factual and legal issues to be resolved, we are unable to make a reasonable estimate of the potential loss or range of losses, if any, that might arise from those matters. In July 2021, Intel introduced a new process node naming structure, and the 7nm process is now Intel 4.

Operating Segments (Tables)

Operating Segments (Tables)	9 Months Ended
	Sep. 25, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net revenue and operating income (loss) for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Net revenue: Client Computing Group Platform $ 8,954 $ 8,762 $ 27,968 $ 25,703 Adjacent 710 1,085 2,410 3,415 9,664 9,847 30,378 29,118 Data Center Group Platform 5,747 5,151 16,261 17,759 Adjacent 749 754 2,254 2,256 6,496 5,905 18,515 20,015 Internet of Things IOTG 1,042 677 2,940 2,230 Mobileye 326 234 1,030 634 1,368 911 3,970 2,864 Non-Volatile Memory Solutions Group 1,105 1,153 3,310 4,150 Programmable Solutions Group 478 411 1,450 1,431 All other 81 106 873 311 Total net revenue $ 19,192 $ 18,333 $ 58,496 $ 57,889 Operating income (loss): Client Computing Group $ 3,317 $ 3,554 $ 11,197 $ 10,621 Data Center Group 2,057 1,903 5,271 8,494 Internet of Things IOTG 276 61 775 374 Mobileye 105 47 361 131 381 108 1,136 505 Non-Volatile Memory Solutions Group 442 29 1,015 285 Programmable Solutions Group 76 40 246 217 All other (1,046) (575) (4,398) (2,328) Total operating income $ 5,227 $ 5,059 $ 14,467 $ 17,794
Revenue from External Customers by Products and Services [Table Text Block]	Disaggregated net revenue for each period was as follows: Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Platform revenue CCG desktop platform $ 2,983 $ 2,483 $ 8,262 $ 7,691 CCG notebook platform 5,953 6,275 19,655 17,976 CCG other platform 1 18 4 51 36 DCG platform 5,747 5,151 16,261 17,759 IOTG platform 948 595 2,679 2,008 15,649 14,508 46,908 45,470 Adjacent revenue 2 3,543 3,825 11,588 12,419 Total revenue $ 19,192 $ 18,333 $ 58,496 $ 57,889 1 Includes our tablet and service provider revenue. 2 Includes all of our non-platform products for CCG, DCG, and IOTG such as modem, Ethernet, and silicon photonics, as well as Mobileye, NSG, and PSG products, as well as revenue included in our "all other" category.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 25, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended (In Millions, Except Per Share Amounts) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Net income available to common stockholders $ 6,823 $ 4,276 $ 15,245 $ 15,042 Weighted average shares of common stock outstanding—basic 4,061 4,188 4,055 4,233 Dilutive effect of employee equity incentive plans 25 23 34 36 Weighted average shares of common stock outstanding—diluted 4,086 4,211 4,089 4,269 Earnings per share—basic $ 1.68 $ 1.02 $ 3.76 $ 3.55 Earnings per share—diluted $ 1.67 $ 1.02 $ 3.73 $ 3.52

Contract Liabilities (Tables)

Contract Liabilities (Tables)	9 Months Ended
	Sep. 25, 2021
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability [Table Text Block]	The following table shows the changes in contract liability balances relating to long-term prepaid supply agreements during the first nine months of 2021: (In Millions) Prepaid supply agreements balance as of December 26, 2020 $ 1,625 Concession payment (950) Prepaids utilized (627) Prepaid supply agreements balance as of September 25, 2021 $ 48

Other Financial Statement Det_2

Other Financial Statement Details (Tables)	9 Months Ended
	Sep. 25, 2021
Other Financial Statement Details [Abstract]
Schedule of Inventory, Current [Table Text Block]	(In Millions) Sep 25, 2021 Dec 26, 2020 Raw materials $ 1,274 $ 908 Work in process 6,304 5,693 Finished goods 2,220 1,826 Total inventories $ 9,798 $ 8,427
Interest and Other, Net [Table Text Block]	Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Interest income $ 37 $ 53 $ 111 $ 229 Interest expense (144) (160) (463) (481) Other, net 31 33 24 (164) Total interest and other, net $ (76) $ (74) $ (328) $ (416)

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	9 Months Ended
	Sep. 25, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Other Charges	Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Employee severance and benefit arrangements $ 21 $ (17) $ 43 $ 90 Litigation charges and other 16 (2) 2,267 54 Asset impairment charges 5 (6) 287 2 Total restructuring and other charges $ 42 $ (25) $ 2,597 $ 146

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 25, 2021
Investments and Cash [Abstract]
Investments Classified by Contractual Maturity Date [Table Text Block]	The fair value of available-for-sale debt investments, by contractual maturity, as of September 25, 2021, was as follows: (In Millions) Fair Value Due in 1 year or less $ 7,823 Due in 1–2 years 631 Due in 2–5 years 322 Due after 5 years — Instruments not due at a single maturity date 2,035 Total $ 10,811
Investment [Table Text Block]	(In Millions) Sep 25, 2021 Dec 26, 2020 Marketable equity securities $ 2,064 $ 1,830 Non-marketable equity securities 3,970 3,304 Equity method investments 16 18 Total $ 6,050 $ 5,152
Gain (Loss) on Securities [Table Text Block]	The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Ongoing mark-to-market adjustments on marketable equity securities $ (192) $ (146) $ (345) $ (84) Observable price adjustments on non-marketable equity securities 79 5 702 142 Impairment charges (38) (40) (111) (233) Sale of equity investments and other¹ 1,858 237 2,124 387 Total gains (losses) on equity investments, net $ 1,707 $ 56 $ 2,370 $ 212 1 Sale of equity investments and other includes realized gains (losses) on sales of non-marketable equity investments, our share of equity method investees' gains (losses) and distributions, and initial fair value adjustments recorded upon a security becoming marketable. Gains and losses for our marketable and non-marketable equity securities for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Net gains (losses) recognized during the period on equity securities $ 346 $ 19 $ 883 $ 102 Less: Net (gains) losses recognized during the period on equity securities sold during the period (46) (12) (189) (87) Unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date $ 300 $ 7 $ 694 $ 15

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	9 Months Ended
	Sep. 25, 2021
Business Combinations [Abstract]
Disposal Groups, Including Discontinued Operations	The carrying amounts of the major classes of NAND assets held for sale included the following: (In Millions) Sep 25, 2021 Dec 26, 2020 Inventories $ 804 $ 962 Property, plant and equipment, net 5,594 4,363 Total assets held for sale $ 6,398 $ 5,325

Borrowings (Tables)

Borrowings (Tables)	9 Months Ended
	Sep. 25, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term Debt Sep 25, 2021 Dec 26, 2020 (In Millions) Effective Interest Rate Amount Amount Floating-rate senior notes: Three-month LIBOR plus 0.35%, due May 2022 0.56 % $ 800 $ 800 Fixed-rate senior notes: 1.70%, due May 2021 — % — 500 3.30%, due October 2021 2.98 % 2,000 2,000 2.35%, due May 2022 1.96 % 750 750 3.10%, due July 2022 2.70 % 1,000 1,000 4.00%, due December 2022¹ 2.95 % 400 417 2.70%, due December 2022 2.28 % 1,500 1,500 4.10%, due November 2023 3.22 % 400 400 2.88%, due May 2024 2.31 % 1,250 1,250 2.70%, due June 2024 2.14 % 600 600 3.40%, due March 2025 3.45 % 1,500 1,500 3.70%, due July 2025 2.16 % 2,250 2,250 2.60%, due May 2026 0.64 % 1,000 1,000 3.75%, due March 2027 3.79 % 1,000 1,000 3.15%, due May 2027 1.22 % 1,000 1,000 1.60%, due August 2028 1.68 % 1,000 — 2.45%, due November 2029 2.39 % 2,000 2,000 3.90%, due March 2030 3.92 % 1,500 1,500 2.00%, due August 2031 2.04 % 1,250 — 4.00%, due December 2032 1.25 % 750 750 4.60%, due March 2040 4.60 % 750 750 2.80%, due August 2041 2.82 % 750 — 4.80%, due October 2041 2.02 % 802 802 4.25%, due December 2042 1.42 % 567 567 4.90%, due July 2045 2.12 % 772 772 4.10%, due May 2046 1.41 % 1,250 1,250 4.10%, due May 2047 1.37 % 1,000 1,000 4.10%, due August 2047 0.92 % 640 640 3.73%, due December 2047 1.77 % 1,967 1,967 3.25%, due November 2049 3.19 % 2,000 2,000 4.75%, due March 2050 4.74 % 2,250 2,250 3.05%, due August 2051 3.07 % 1,250 — 3.10%, due February 2060 3.11 % 1,000 1,000 4.95%, due March 2060 4.99 % 1,000 1,000 3.20%, due August 2061 3.22 % 750 — Oregon and Arizona bonds: 2.40%-2.70%, due December 2035 - 2040 2.49 % 423 423 5.00%, due March 2049 2.12 % 138 138 5.00%, due June 2049 2.15 % 438 438 Total Senior Notes and Other Borrowings 39,697 35,214 Unamortized premium/discount and issuance costs (402) (378) Hedge accounting fair value adjustments 1,009 1,565 Long-term debt 40,304 36,401 Current portion of long-term debt (4,694) (2,504) Total long-term debt $ 35,610 $ 33,897 1 To manage foreign currency risk associated with the Australian-dollar-denominated notes issued in 2015, we entered into currency interest rate swaps with an aggregate notional amount of $396 million, which effectively converted these notes to U.S.-dollar-denominated notes. For further discussion on derivatives in cash flow hedging relationships, see "Note 12: Derivative Financial Instruments."

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 25, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Sep 25, 2021 Dec 26, 2020 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 736 $ — $ 736 $ — $ 50 $ — $ 50 Financial institution instruments¹ 2,035 718 — 2,753 2,781 636 — 3,417 Government debt² 2,200 164 — 2,364 — — — — Reverse repurchase agreements — 1,350 — 1,350 — 1,900 — 1,900 Short-term investments: Corporate debt — 870 — 870 — 428 — 428 Financial institution instruments¹ — 2,066 — 2,066 — 1,179 — 1,179 Government debt² — 1,068 — 1,068 — 685 — 685 Trading assets: Corporate debt — 5,121 — 5,121 — 3,815 — 3,815 Financial institution instruments¹ 67 4,014 — 4,081 131 2,847 — 2,978 Government debt² — 13,559 — 13,559 — 8,945 — 8,945 Other current assets: Derivative assets 4 323 — 327 48 644 — 692 Loans receivable³ — 211 — 211 — 439 — 439 Marketable equity securities 272 1,792 — 2,064 136 1,694 — 1,830 Other long-term investments: Corporate debt — 684 — 684 — 1,520 — 1,520 Financial institution instruments¹ — 203 — 203 — 257 — 257 Government debt² — 66 — 66 — 415 — 415 Other long-term assets: Derivative assets — 961 13 974 — 1,520 30 1,550 Loans receivable³ — — — — — 157 — 157 Total assets measured and recorded at fair value $ 4,578 $ 33,906 $ 13 $ 38,497 $ 3,096 $ 27,131 $ 30 $ 30,257 Liabilities Other accrued liabilities: Derivative liabilities $ 29 $ 527 $ — $ 556 $ — $ 810 $ — $ 810 Other long-term liabilities: Derivative liabilities — 9 — 9 — 5 — 5 Total liabilities measured and recorded at fair value $ 29 $ 536 $ — $ 565 $ — $ 815 $ — $ 815 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of commercial paper, certificates of deposit, time deposits, and notes and bonds issued by financial institutions. 2 Level 1 investments consist primarily of U.S. Treasury securities. Level 2 investments consist primarily of U.S. agency notes and non-U.S. government debt. 3 The fair value of our loans receivable for which we elected the fair value option did not significantly differ from the contractual principal balance.

Other Comprehensive Income (L_2

Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 25, 2021
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The changes in accumulated other comprehensive income (loss) by component and related tax effects in the first nine months of 2021 were as follows: (In Millions) Unrealized Holding Gains (Losses) on Derivatives Actuarial Valuation and Other Pension Expenses Translation Adjustments and Other Total Balance as of December 26, 2020 $ 731 $ (1,565) $ 83 $ (751) Other comprehensive income (loss) before reclassifications (313) 5 (41) (349) Amounts reclassified out of accumulated other comprehensive income (loss) (196) 47 (14) (163) Tax effects 119 (14) 11 116 Other comprehensive income (loss) (390) 38 (44) (396) Balance as of September 25, 2021 $ 341 $ (1,527) $ 39 $ (1,147)

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 25, 2021
Derivative [Line Items]
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	Total gross notional amounts for outstanding derivatives at the end of each period were as follows: (In Millions) Sep 25, 2021 Dec 26, 2020 Foreign currency contracts $ 35,012 $ 31,209 Interest rate contracts 14,960 14,461 Other 2,419 2,026 Total $ 52,391 $ 47,696
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value of Derivative Instruments Sep 25, 2021 Dec 26, 2020 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 99 $ 74 $ 551 $ 2 Interest rate contracts 966 — 1,498 — Total derivatives designated as hedging instruments 1,065 74 2,049 2 Derivatives not designated as hedging instruments: Foreign currency contracts 3 221 378 142 685 Interest rate contracts 11 84 3 128 Equity contracts 4 29 48 — Total derivatives not designated as hedging instruments 236 491 193 813 Total derivatives $ 1,301 $ 565 $ 2,242 $ 815 1 Derivative assets are recorded as other assets, current and non-current. 2 Derivative liabilities are recorded as other liabilities, current and non-current. 3 The majority of these instruments mature within 12 months. The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheet in Which the Hedged Item is Included Carrying Amount of the Hedged Item Asset/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Sep 25, 2021 Dec 26, 2020 Sep 25, 2021 Dec 26, 2020 Long-term debt $ (12,963) $ (13,495) $ (966) $ (1,498)
Offsetting Assets [Table Text Block]	The gross amounts of our derivative instruments and reverse repurchase agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 25, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,295 $ — $ 1,295 $ (329) $ (913) $ 53 Reverse repurchase agreements 1,350 — 1,350 — (1,350) — Total assets 2,645 — 2,645 (329) (2,263) 53 Liabilities: Derivative liabilities subject to master netting arrangements 408 — 408 (329) (79) — Total liabilities $ 408 $ — $ 408 $ (329) $ (79) $ — Dec 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master netting arrangements 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ —
Offsetting Liabilities [Table Text Block]	The gross amounts of our derivative instruments and reverse repurchase agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 25, 2021 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,295 $ — $ 1,295 $ (329) $ (913) $ 53 Reverse repurchase agreements 1,350 — 1,350 — (1,350) — Total assets 2,645 — 2,645 (329) (2,263) 53 Liabilities: Derivative liabilities subject to master netting arrangements 408 — 408 (329) (79) — Total liabilities $ 408 $ — $ 408 $ (329) $ (79) $ — Dec 26, 2020 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 2,235 $ — $ 2,235 $ (264) $ (1,904) $ 67 Reverse repurchase agreements 1,900 — 1,900 — (1,900) — Total assets 4,135 — 4,135 (264) (3,804) 67 Liabilities: Derivative liabilities subject to master netting arrangements 711 — 711 (264) (447) — Total liabilities $ 711 $ — $ 711 $ (264) $ (447) $ —
Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Location of Gains (Losses) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Foreign currency contracts Interest and other, net $ 170 $ (166) $ 382 $ (228) Interest rate contracts Interest and other, net (7) (3) 14 (94) Other Various 84 138 279 95 Total $ 247 $ (31) $ 675 $ (227)
Interest and other, net [Member] | Fair Value Hedging
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) Recognized in Consolidated Condensed Statements of Income on Derivatives Three Months Ended Nine Months Ended (In Millions) Sep 25, 2021 Sep 26, 2020 Sep 25, 2021 Sep 26, 2020 Interest rate contracts $ (55) $ (36) $ (532) $ 996 Hedged items 55 36 532 (996) Total $ — $ — $ — $ —

Business Segments (Detail)

Business Segments (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Segment Reporting Information [Line Items]
Net revenue	$ 19,192	$ 18,333	$ 58,496	$ 57,889
Operating Income (Loss)	5,227	5,059	14,467	17,794
Platform
Segment Reporting Information [Line Items]
Net revenue	15,649	14,508	46,908	45,470
Adjacent revenue
Segment Reporting Information [Line Items]
Net revenue	3,543	3,825	11,588	12,419
Internet of Things [Member]
Segment Reporting Information [Line Items]
Net revenue	1,368	911	3,970	2,864
Operating Income (Loss)	381	108	1,136	505
Client Computing Group [Member]
Segment Reporting Information [Line Items]
Net revenue	9,664	9,847	30,378	29,118
Operating Income (Loss)	3,317	3,554	11,197	10,621
Client Computing Group [Member] | Platform
Segment Reporting Information [Line Items]
Net revenue	8,954	8,762	27,968	25,703
Client Computing Group [Member] | Adjacent revenue
Segment Reporting Information [Line Items]
Net revenue	710	1,085	2,410	3,415
Data Center Group [Member]
Segment Reporting Information [Line Items]
Net revenue	6,496	5,905	18,515	20,015
Operating Income (Loss)	2,057	1,903	5,271	8,494
Data Center Group [Member] | Adjacent revenue
Segment Reporting Information [Line Items]
Net revenue	749	754	2,254	2,256
Data Center Group [Member] | DCG platform
Segment Reporting Information [Line Items]
Net revenue	5,747	5,151	16,261	17,759
Internet of Things Group [Member]
Segment Reporting Information [Line Items]
Net revenue	1,042	677	2,940	2,230
Operating Income (Loss)	276	61	775	374
Mobileye [Member]
Segment Reporting Information [Line Items]
Net revenue	326	234	1,030	634
Operating Income (Loss)	105	47	361	131
Non-Volatile Memory Solutions Group [Member]
Segment Reporting Information [Line Items]
Net revenue	1,105	1,153	3,310	4,150
Operating Income (Loss)	442	29	1,015	285
Programmable Solutions Group [Member]
Segment Reporting Information [Line Items]
Net revenue	478	411	1,450	1,431
Operating Income (Loss)	76	40	246	217
All other [Member]
Segment Reporting Information [Line Items]
Net revenue	81	106	873	311
Operating Income (Loss)	$ (1,046)	$ (575)	$ (4,398)	$ (2,328)

Product Information (Detail)

Product Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Revenue from External Customer [Line Items]
Net revenue	$ 19,192	$ 18,333	$ 58,496	$ 57,889
Desktop platform
Revenue from External Customer [Line Items]
Net revenue	2,983	2,483	8,262	7,691
Notebook platform
Revenue from External Customer [Line Items]
Net revenue	5,953	6,275	19,655	17,976
Other platform
Revenue from External Customer [Line Items]
Net revenue	18	4	51	36
IOTG platform
Revenue from External Customer [Line Items]
Net revenue	948	595	2,679	2,008
Platform
Revenue from External Customer [Line Items]
Net revenue	15,649	14,508	46,908	45,470
Adjacent revenue
Revenue from External Customer [Line Items]
Net revenue	$ 3,543	$ 3,825	$ 11,588	$ 12,419

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Earnings Per Share [Abstract]
Net income	$ 6,823	$ 4,276	$ 15,245	$ 15,042
Weighted average shares of common stock outstanding—basic	4,061	4,188	4,055	4,233
Dilutive effect of employee equity incentive plans (shares)	25	23	34	36
Weighted average shares of common stock outstanding—diluted	4,086	4,211	4,089	4,269
Earnings per share - Basic (in dollars per share)	$ 1.68	$ 1.02	$ 3.76	$ 3.55
Earnings per share - Diluted (in dollars per share)	$ 1.67	$ 1.02	$ 3.73	$ 3.52

Contract Liabilities (Details)

Contract Liabilities (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 25, 2021	Jun. 26, 2021	Dec. 26, 2020
Capitalized Contract Cost [Line Items]
Contract with customer, liability	$ 351		$ 1,900
Contract with customer, liability, concession payments	950
Contract liability balance, contract termination		$ 1,600
Prepaid Supply Agreements
Capitalized Contract Cost [Line Items]
Contract with customer, liability	48		$ 1,625
Contract with customer, liability, concession payments	(950)
Contract with customer, liability, revenue recognized	(627)
Contract with customer, liability, revenue retained in balance	$ 584

Other Financial Statement Det_3

Other Financial Statement Details Inventories (Details) - USD ($) $ in Millions	Sep. 25, 2021	Dec. 26, 2020
Inventory, Net [Abstract]
Raw materials	$ 1,274	$ 908
Work in process	6,304	5,693
Finished goods	2,220	1,826
Total inventories	$ 9,798	$ 8,427

Other Financial Statement Det_4

Other Financial Statement Details Interest and Other, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Other Nonoperating Income (Expense) [Abstract]
Interest income	$ 37	$ 53	$ 111	$ 229
Interest expense	(144)	(160)	(463)	(481)
Other, net	31	33	24	(164)
Total interest and other, net	(76)	(74)	(328)	(416)
Interest Costs Capitalized	$ 95	$ 81	$ 288	$ 251

Restructuring and Other Charg_3

Restructuring and Other Charges (Detail) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 25, 2021	Jun. 26, 2021	Mar. 27, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Restructuring and Related Activities [Abstract]
Employee severance and benefit arrangements	$ 21			$ (17)	$ 43	$ 90
Litigation charges and other	16			(2)	2,267	54
Asset impairment charges	5			(6)	287	2
Restructuring and other charges	$ 42			$ (25)	$ 2,597	$ 146
Litigation charges			$ 2,200
Goodwill impairment charge		$ 237

Investments, Trading Assets (De

Investments, Trading Assets (Detail) - Debt Securities [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt Securities, Trading, Unrealized Gain (Loss)	$ (144)	$ 205	$ (329)	$ 347
Unrealized Gain (Loss) on Derivatives	$ 156	$ (163)	$ 346	$ (334)

Investments, Available-for-Sale

Investments, Available-for-Sale Debt Investments (Detail) - USD ($) $ in Millions	Sep. 25, 2021	Dec. 26, 2020
Investments and Cash [Abstract]
Debt Securities, Available-for-sale, Amortized Cost	$ 10,800	$ 7,800
Due in 1 year or less	7,823
Due in 1–2 years	631
Due in 2–5 years	322
Due after 5 years	0
Instruments not due at a single maturity date	2,035
Total	$ 10,811

Investments, Equity Investments

Investments, Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020	Dec. 26, 2020
Investments, All Other Investments [Abstract]
Marketable Securities	$ 2,064		$ 2,064		$ 1,830
Cost Method Investments	3,970		3,970		3,304
Equity Method Investments	16		16		18
Equity Investments	6,050		6,050		$ 5,152
Mark to market on marketable equity securities1	(192)	$ (146)	(345)	$ (84)
Observable price adjustments on non-marketable	79	5	702	142
Impairments	(38)	(40)	(111)	(233)
Other Net Equity Investments	1,858	237	2,124	387
Gain (Loss) on Investments	1,707	56	2,370	212
Net gains (losses) recognized during the period on equity securities	346	19	883	102
Less: Net (gains) losses recognized during the period on equity securities sold during the period	(46)	(12)	(189)	(87)
Unrealized gains (losses) recognized during the reporting period on equity securities still held at the reporting date	$ 300	$ 7	$ 694	$ 15

Investments - Equity Investment

Investments - Equity Investments, Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020
Schedule of Equity Method Investments [Line Items]
Initial fair value adjustments for companies that went public	$ 447
Special dividend recognized in sale of equity investments and other	1,858	$ 237	$ 2,124	$ 387
McAfee
Schedule of Equity Method Investments [Line Items]
Special dividend recognized in sale of equity investments and other	$ 1,100

Investments - Bejing Unisoc Tec

Investments - Bejing Unisoc Technology (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 25, 2021	Mar. 27, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020	Dec. 26, 2020
Schedule of Investments [Line Items]
Gains (losses) on equity investments, net	$ 1,707		$ 56	$ 2,370	$ 212
Bejing Unisoc Technology Ltd.
Schedule of Investments [Line Items]
Gains (losses) on equity investments, net		$ 471
Net book value of nonmarketable equity investment	$ 1,100			$ 1,100		$ 658

Acquisitions and Divestitures_2

Acquisitions and Divestitures (Details) - USD ($) $ in Millions	Nov. 01, 2021	Oct. 19, 2020	May 04, 2020	Mar. 31, 2025	Oct. 31, 2021	Sep. 25, 2021	Dec. 26, 2020
Business Acquisition [Line Items]
Goodwill						$ 26,786	$ 26,971
Consideration transferred for divestiture of business		$ 9,000
Forecast
Business Acquisition [Line Items]
Proceeds from divestiture	$ 7,000			$ 2,000
Additions to held for sale NAND property, plant and equipment					$ 1,800
Moovit
Business Acquisition [Line Items]
Total consideration			$ 915
Goodwill			638
Intangible assets acquired			$ 331

Acquisitions and Divestitures -

Acquisitions and Divestitures - Schedule of Assets Held for Sale (Details) - USD ($) $ in Millions	Sep. 25, 2021	Dec. 26, 2020
Business Combinations [Abstract]
Inventories	$ 804	$ 962
Property, plant and equipment, net	5,594	4,363
Total assets held for sale	$ 6,398	$ 5,325

Borrowings Borrowings, Narrativ

Borrowings Borrowings, Narrative (Details)	3 Months Ended
	Sep. 25, 2021USD ($)
Senior Notes
Debt Instrument [Line Items]
face amount of debt issued	$ 5,000,000,000
Commercial Paper
Debt Instrument [Line Items]
Authorization to borrow	10,000,000,000
Variable Rate Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Variable rate revolving credit facility	5,000,000,000
Senior Notes due May 2021 | Senior Notes
Debt Instrument [Line Items]
Debt settled during period	$ 500,000,000

Borrowings, Long-term Debt (Det

Borrowings, Long-term Debt (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 25, 2021	Dec. 26, 2020
Debt Instrument [Line Items]
Amount	$ 39,697	$ 35,214
Unamortized premium/discount and issuance costs	(402)	(378)
Long-term debt	40,304	36,401
Current portion of long-term debt	(4,694)	(2,504)
Total long-term debt	35,610	33,897
Notional amount	52,391	47,696
Fair Value Hedging | Interest Rate Swap
Debt Instrument [Line Items]
Hedge accounting fair value adjustments	$ 1,009	1,565
Floating-rate senior notes: Three-month LIBOR plus 0.35%, due May 2022
Debt Instrument [Line Items]
Effective Interest Rate	0.56%
Amount	$ 800	800
1.70%, due May 2021
Debt Instrument [Line Items]
Effective Interest Rate	0.00%
Amount	$ 0	500
3.30%, due October 2021
Debt Instrument [Line Items]
Effective Interest Rate	2.98%
Amount	$ 2,000	2,000
2.35%, due May 2022
Debt Instrument [Line Items]
Effective Interest Rate	1.96%
Amount	$ 750	750
3.10%, due July 2022
Debt Instrument [Line Items]
Effective Interest Rate	2.70%
Amount	$ 1,000	1,000
4.00%, due December 2022¹
Debt Instrument [Line Items]
Effective Interest Rate	2.95%
Amount	$ 400	417
4.00%, due December 2022¹ | Cross Currency Interest Rate Contract
Debt Instrument [Line Items]
Notional amount	$ 396
2.70%, due December 2022
Debt Instrument [Line Items]
Effective Interest Rate	2.28%
Amount	$ 1,500	1,500
4.10%, due November 2023
Debt Instrument [Line Items]
Effective Interest Rate	3.22%
Amount	$ 400	400
2.88%, due May 2024
Debt Instrument [Line Items]
Effective Interest Rate	2.31%
Amount	$ 1,250	1,250
2.70%, due June 2024
Debt Instrument [Line Items]
Effective Interest Rate	2.14%
Amount	$ 600	600
3.40%, due March 2025
Debt Instrument [Line Items]
Effective Interest Rate	3.45%
Amount	$ 1,500	1,500
3.70%, due July 2025
Debt Instrument [Line Items]
Effective Interest Rate	2.16%
Amount	$ 2,250	2,250
2.60%, due May 2026
Debt Instrument [Line Items]
Effective Interest Rate	0.64%
Amount	$ 1,000	1,000
3.75%, due March 2027
Debt Instrument [Line Items]
Effective Interest Rate	3.79%
Amount	$ 1,000	1,000
3.15%, due May 2027
Debt Instrument [Line Items]
Effective Interest Rate	1.22%
Amount	$ 1,000	1,000
2.45%, due November 2029
Debt Instrument [Line Items]
Effective Interest Rate	2.39%
Amount	$ 2,000	2,000
3.90%, due March 2030
Debt Instrument [Line Items]
Effective Interest Rate	3.92%
Amount	$ 1,500	1,500
4.00%, due December 2032
Debt Instrument [Line Items]
Effective Interest Rate	1.25%
Amount	$ 750	750
4.60%, due March 2040
Debt Instrument [Line Items]
Effective Interest Rate	4.60%
Amount	$ 750	750
4.80%, due October 2041
Debt Instrument [Line Items]
Effective Interest Rate	2.02%
Amount	$ 802	802
4.25%, due December 2042
Debt Instrument [Line Items]
Effective Interest Rate	1.42%
Amount	$ 567	567
4.90%, due July 2045
Debt Instrument [Line Items]
Effective Interest Rate	2.12%
Amount	$ 772	772
4.10%, due May 2046
Debt Instrument [Line Items]
Effective Interest Rate	1.41%
Amount	$ 1,250	1,250
4.10%, due May 2047
Debt Instrument [Line Items]
Effective Interest Rate	1.37%
Amount	$ 1,000	1,000
4.10%, due August 2047
Debt Instrument [Line Items]
Effective Interest Rate	0.92%
Amount	$ 640	640
3.73%, due December 2047
Debt Instrument [Line Items]
Effective Interest Rate	1.77%
Amount	$ 1,967	1,967
3.25%, due November 2049
Debt Instrument [Line Items]
Effective Interest Rate	3.19%
Amount	$ 2,000	2,000
4.75%, due March 2050
Debt Instrument [Line Items]
Effective Interest Rate	4.74%
Amount	$ 2,250	2,250
3.10%, due February 2060
Debt Instrument [Line Items]
Effective Interest Rate	3.11%
Amount	$ 1,000	1,000
4.95%, due March 2060
Debt Instrument [Line Items]
Effective Interest Rate	4.99%
Amount	$ 1,000	1,000
2.40%-2.70%, due December 2035 - 2040
Debt Instrument [Line Items]
Effective Interest Rate	2.49%
Amount	$ 423	423
5.00%, due March 2049
Debt Instrument [Line Items]
Effective Interest Rate	2.12%
Amount	$ 138	138
5.00%, due June 2049
Debt Instrument [Line Items]
Effective Interest Rate	2.15%
Amount	$ 438	438
Fixed-rate Senior Notes, 1.60% due August 2028
Debt Instrument [Line Items]
Effective Interest Rate	1.68%
Amount	$ 1,000	0
Fixed-rate Senior Notes, 2.00% due August 2031
Debt Instrument [Line Items]
Effective Interest Rate	2.04%
Amount	$ 1,250	0
Fixed-rate Senior Notes, 2.80%, due August 2041
Debt Instrument [Line Items]
Effective Interest Rate	2.82%
Amount	$ 750	0
Fixed-rate Senior Notes, 3.05% due August 2051
Debt Instrument [Line Items]
Effective Interest Rate	3.07%
Amount	$ 1,250	0
Fixed-rate Senior Notes, 3.20% due August 2061
Debt Instrument [Line Items]
Effective Interest Rate	3.22%
Amount	$ 750	$ 0

Fair Value (Detail)

Fair Value (Detail) - USD ($) $ in Millions	Sep. 25, 2021	Dec. 26, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	$ 1,350	$ 1,900
Trading assets, Fair Value Disclosure	22,761	15,738
Derivative assets, Fair Value Disclosure	1,295	2,235
Derivative liabilities, Fair Value Disclosure	408	711
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	38,497	30,257
Liabilities, Fair Value Disclosure	565	815
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Grants & loans Receivable, Reverse repurchase agreements, CV	399	139
Short-term and Long-term Debt, Fair Value	44,600	40,900
Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	5,121	3,815
Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	4,081	2,978
Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	13,559	8,945
Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,064	1,830
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	1,350	1,900
Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	736	50
Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,753	3,417
Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,364	0
Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	870	428
Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,066	1,179
Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,068	685
Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	327	692
Loans receivable, Fair Value Disclosure	211	439
Other Long-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	684	1,520
Other Long-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	203	257
Other Long-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	66	415
Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	974	1,550
Loans receivable, Fair Value Disclosure	0	157
Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	556	810
Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	9	5
Level 1 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	4,578	3,096
Liabilities, Fair Value Disclosure	29	0
Level 1 [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 1 [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	67	131
Level 1 [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 1 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	272	136
Level 1 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 1 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,035	2,781
Level 1 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,200	0
Level 1 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	4	48
Loans receivable, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Loans receivable, Fair Value Disclosure	0	0
Level 1 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	29	0
Level 1 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	33,906	27,131
Liabilities, Fair Value Disclosure	536	815
Level 2 [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	5,121	3,815
Level 2 [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	4,014	2,847
Level 2 [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	13,559	8,945
Level 2 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,792	1,694
Level 2 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	1,350	1,900
Level 2 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	736	50
Level 2 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	718	636
Level 2 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	164	0
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	870	428
Level 2 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,066	1,179
Level 2 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,068	685
Level 2 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	323	644
Loans receivable, Fair Value Disclosure	211	439
Level 2 [Member] | Other Long-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	684	1,520
Level 2 [Member] | Other Long-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	203	257
Level 2 [Member] | Other Long-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	66	415
Level 2 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	961	1,520
Loans receivable, Fair Value Disclosure	0	157
Level 2 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	527	810
Level 2 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	9	5
Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	13	30
Liabilities, Fair Value Disclosure	0	0
Level 3 [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 3 [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 3 [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Trading assets, Fair Value Disclosure	0	0
Level 3 [Member] | Marketable Equity Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 3 [Member] | Cash Equivalents [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Cash Equivalents [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Short-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Current Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Loans receivable, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Fixed Income Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Investments [Member] | Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Assets [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	13	30
Loans receivable, Fair Value Disclosure	0	0
Level 3 [Member] | Other Accrued Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 3 [Member] | Other Long-Term Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	$ 0	$ 0

Other Comprehensive Income (L_3

Other Comprehensive Income (Loss), Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020	Dec. 26, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months			$ 90
Other comprehensive income (loss)	$ (52)	$ 212	(396)	$ 340
Unrealized holding gains (losses) on available-for-sale investments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	341		341		$ 731
Other comprehensive income (loss) before reclassifications			(313)
Amounts reclassified out of accumulated other comprehensive income (loss)			(196)
Tax effects			119
Other comprehensive income (loss)			(390)
Unrealized holding gains (losses) on derivatives [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	(1,527)		(1,527)		(1,565)
Other comprehensive income (loss) before reclassifications			5
Amounts reclassified out of accumulated other comprehensive income (loss)			47
Tax effects			(14)
Other comprehensive income (loss)			38
Actuarial gains (losses) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	39		39		83
Other comprehensive income (loss) before reclassifications			(41)
Amounts reclassified out of accumulated other comprehensive income (loss)			(14)
Tax effects			11
Other comprehensive income (loss)			(44)
Foreign currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income (loss)	$ (1,147)		(1,147)		$ (751)
Other comprehensive income (loss) before reclassifications			(349)
Amounts reclassified out of accumulated other comprehensive income (loss)			(163)
Tax effects			116
Other comprehensive income (loss)			$ (396)

Derivative Financial Instrume_3

Derivative Financial Instruments (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 25, 2021	Sep. 26, 2020	Sep. 25, 2021	Sep. 26, 2020	Dec. 26, 2020
Notional Disclosures [Abstract]
Notional amount	$ 52,391		$ 52,391		$ 47,696
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,295		1,295		2,235
Derivative Assets Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0		0		0
Derivative Assets Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	1,295		1,295		2,235
Derivative Assets, Financial Instruments Not Offset in the Balance Sheet	(329)		(329)		(264)
Derivative Assets, Cash Collateral Not Offset in the Balance Sheet	(913)		(913)		(1,904)
Derivative Assets Subject to Master Netting Arrangements, Net Amount	53		53		67
Reverse Repurchase Agreements, Gross Amounts Recognized	1,350		1,350		1,900
Reverse Repurchase Agreements, Gross Amounts Offset In The Balance Sheet	0		0		0
Reverse Repurchase Agreements, Net Amount Presented in the Balance Sheet	1,350		1,350		1,900
Reverse Repurchase Agreements, Financial Instruments Not Offset in the Balance Sheet	0		0		0
Reverse Repurchase Agreements, Cash Collateral Not Offset in the Balance Sheet	(1,350)		(1,350)		(1,900)
Reverse Repurchase Agreements, Net Amount	0		0		0
Total Assets, Gross Amounts Recognized	2,645		2,645		4,135
Total Assets, Gross Amounts Offset in the Balance Sheet	0		0		0
Total Assets, Net Amounts Presented in the Balance Sheet	2,645		2,645		4,135
Total Assets, Financial Instruments, Not Offset in the Balance Sheet	(329)		(329)		(264)
Total Assets, Cash and Non Cash Collateral, Not Offset in the Balance Sheet	(2,263)		(2,263)		(3,804)
Total Assets, Net Amount	53		53		67
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	408		408		711
Derivative Liabilities Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0		0		0
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	408		408		711
Derivative Liabilities, Financial Instruments Not Offset in the Balance Sheet	(329)		(329)		(264)
Derivative Liabilities, Cash Collateral Not Offset in the Balance Sheet	(79)		(79)		(447)
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount	0		0		0
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	55	$ 36	532	$ (996)
Net Change In Unrealized Gain (Loss) Recognized In Income Statement On Fair Value Hedging Instruments And On Hedged Item In Fair Value Hedge	0	0	0	0
Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,301		1,301		2,242
Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	565		565		815
Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	1,065		1,065		2,049
Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	74		74		2
Not Designated as Hedging Instrument [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	247	(31)	675	(227)
Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	236		236		193
Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	491		491		813
Foreign currency contracts
Notional Disclosures [Abstract]
Notional amount	35,012		35,012		31,209
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net [Abstract]
Before-tax net gains or losses attributed to cash flow hedges, recognized in other comprehensive income (loss)	(28)	267	(313)	286
Foreign currency contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	99		99		551
Foreign currency contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	74		74		2
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Interest and other, net [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	170	(166)	382	(228)
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	221		221		142
Foreign currency contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	378		378		685
Interest rate contracts
Notional Disclosures [Abstract]
Notional amount	14,960		14,960		14,461
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(55)	(36)	(532)	996
Interest rate contracts | Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	966		966		1,498
Interest rate contracts | Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	0		0		0
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Interest and other, net [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	(7)	(3)	14	(94)
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	11		11		3
Interest rate contracts | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	84		84		128
Other
Notional Disclosures [Abstract]
Notional amount	2,419		2,419		2,026
Other | Not Designated as Hedging Instrument [Member] | Various [Member]
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	84	$ 138	279	$ 95
Other | Not Designated as Hedging Instrument [Member] | Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	4		4		48
Other | Not Designated as Hedging Instrument [Member] | Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	29		29		0
Interest Rate Swap | Fair Value Hedging
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives			(1,009)		(1,565)
Interest Rate Swap | Long-term Debt | Fair Value Hedging
Derivative [Line Items]
Derivative, Amount of Hedged Item	12,000		12,000		12,000
Derivative, Fair Value, Net	$ (12,963)		(12,963)		(13,495)
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives			$ (966)		$ (1,498)

Contingencies (Detail)

Contingencies (Detail) - 1 months ended May 31, 2009 € in Billions, $ in Billions	EUR (€)	USD ($)
EC Fine [Member]
Loss Contingencies [Line Items]
Loss contingency, damages paid, value	€ 1.1	$ 1.4